Related Experiment Video
Updated: May 26, 2026
05:58
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
InforMatrix: ADP antagonists in acute coronary syndromes
Robert Janknegt1, Lex Ruiters, Hugo Ten Cate
1Orbis Medisch Centrum , P.O. Box 5500, 6130 MB Sittard-Geleen , the Netherlands. r.janknegt@orbisconcern.nl
Expert Opinion on Pharmacotherapy
|January 7, 2012
Summary
InforMatrix provides a rational framework for selecting pharmacotherapies, comparing ADP antagonists like clopidogrel, prasugrel, and ticagrelor based on efficacy, safety, and cost. It aids formulary decisions by quantifying drug property importance.
Area of Science:
- Pharmacology
- Health Economics
- Clinical Decision Support
Background:
- InforMatrix is an interactive model supporting rational pharmacotherapeutic strategy selection through transparent methodologies.
- It facilitates evidence-based drug choice by evaluating multiple criteria.
Purpose of the Study:
- To apply the InforMatrix model to compare key adenosine diphosphate (ADP) antagonists.
- To evaluate clopidogrel, prasugrel, and ticagrelor using defined selection criteria for acute coronary syndrome treatment.
Main Methods:
- InforMatrix was utilized to compare clopidogrel, prasugrel, and ticagrelor.
- Selection criteria included efficacy, safety, tolerability, ease of use, applicability, and cost.
- Comparative studies, including placebo-controlled and double-blind trials, informed the assessment.
Main Results:
- The comparison highlighted differences in efficacy, safety, and acquisition costs among ADP antagonists.
- Generic clopidogrel presents a significant cost advantage where available.
- Potential efficacy benefits of prasugrel and ticagrelor require balancing against clopidogrel's extensive clinical data.
Conclusions:
- InforMatrix quantifies differences in drug properties and user-assigned importance, fostering rational formulary decision-making.
- The model supports discussions on the relative merits of clopidogrel, prasugrel, and ticagrelor, particularly regarding efficacy and cost.
- It aids in navigating the complexities of drug selection for acute coronary syndromes.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...